Peptide bloodwork is not a special panel. It is an ordinary set of markers, taken at sensible intervals, and read as a trend rather than a single result. That is the whole idea, and it is worth stating plainly because most of what circulates online treats bloodwork as either a ritual or a verdict.
Two things make it useful. The first is a baseline taken before anything changes, because a number only means something compared with your own normal. The second is knowing which markers the compounds you are reading about actually move. So this peptide bloodwork guide covers the panel, the timing, and the specific markers that the labels and trials point to.
What peptide bloodwork can and cannot tell you
It can show you what your body is doing, in numbers, on a given morning. It can catch a liver enzyme climbing, a haematocrit drifting up, or a glucose figure that has moved out of range. Those are real signals, and they appear long before you feel anything.
However, it cannot tell you whether an unapproved peptide is “working”. Nobody has published human pharmacokinetics for most research peptides, so no marker has been validated against them. A change in your IGF-1 or your ALT is a fact about your body. Whether a specific vial caused it is a guess unless you controlled everything else. If the vial side is what you are still working out, the reconstitution guide and the guide to how long a mixed vial lasts cover it.
Therefore treat the panel as monitoring rather than measurement. It tells you whether you are still inside safe ranges, and it gives a clinician something concrete to work with. That is more than most people in this market have.
The core panel
Four groups cover most of what matters. A doctor will recognise all of them, and a laboratory will run them as standard panels rather than exotic tests.
| Group | Markers | Why they matter here |
|---|---|---|
| Blood count | Haemoglobin, haematocrit, white cells, platelets | Haematocrit rises with androgens, and blood viscosity is the risk that follows |
| Lipids | Total cholesterol, LDL, HDL, triglycerides | Orals and androgens push HDL down, and that change reverses slowly |
| Liver | ALT, AST, GGT, bilirubin, alkaline phosphatase | Oral 17-alpha-alkylated compounds are the classic cause of cholestasis |
| Metabolic and hormonal | Fasting glucose, HbA1c, IGF-1, total and free testosterone, oestradiol, LH, FSH, prolactin | This is where growth hormone, GLP-1s and hCG show up first |
Blood pressure is not a blood test, and it belongs in the same conversation. A rise there is one of the earliest changes worth acting on.
A full blood count and a lipid profile are routine. Liver enzymes are routine. The hormonal panel usually needs a reason, and “I am tracking changes” is a reasonable one to give a clinician.
Markers that move on specific compounds
This is where general advice usually stops and the labels are more useful. Each of these compounds has a documented effect on a marker, and each has a monitoring implication.
| Compound | Markers to watch | What the label or trial says |
|---|---|---|
| Growth hormone (somatropin) | IGF-1, fasting glucose | IGF-1 is the standard way to monitor therapy, and glucose handling can worsen |
| GLP-1 receptor agonists | Creatinine and eGFR, plus lipase if symptoms appear | The label advises renal monitoring during dehydration, and lipase can rise without pancreatitis |
| hCG | Total testosterone, oestradiol | Testosterone rises, and some of it converts to oestradiol through aromatase |
| Oral anabolic steroids | ALT, AST, bilirubin, lipids | Liver injury ranges from mild enzyme rises to prolonged cholestasis |
| Research peptides with no human data | None validated | No human pharmacokinetics, therefore no monitoring marker to point at |
The last row is the honest one. For BPC-157, TB-500 and most of the newer research compounds, nobody has published human data of the kind that would let anyone say “check this marker at this interval”. Any page that gives you one is inventing it.
When to test
For peptide bloodwork, a single result is a snapshot, and snapshots mislead. What you want is four points on the same set of markers, taken at predictable stages, so the direction of travel is visible.
| Stage | What to run | Why then |
|---|---|---|
| Before anything starts | The full core panel, plus blood pressure | This is your reference value, and no later number means anything without it |
| Week 4 to 6 | Liver enzymes, blood count, blood pressure | Early movers show up here, while the change is still reversible |
| Week 8 to 12 | Full panel again, including lipids and hormones | Lipids and haematocrit need weeks to shift, so earlier testing wastes the draw |
| After you stop | Full panel at 4 to 6 weeks, and again at 3 months | Some changes reverse quickly and others do not, so you need both points |
Fast the same way every time, test at the same time of day, and use the same laboratory if you can. Consistency matters more than the exact schedule, because you are comparing your numbers with your own earlier numbers.
What the labels actually say
Regulators write monitoring instructions into approved products, and those instructions are the closest thing to an evidence-based peptide bloodwork schedule that exists in this area.
- Growth hormone. IGF-1 is the standard monitoring marker, because it reflects growth hormone exposure more stably than a single GH measurement does.
- GLP-1 agonists. The label points to renal function when nausea, vomiting or diarrhoea could cause dehydration. Lipase and amylase can rise without pancreatitis, so a number alone does not diagnose anything.
- hCG. Testosterone rises because hCG mimics luteinising hormone. Some of that testosterone converts to oestradiol, which is why both are worth looking at together.
- Oral anabolic steroids. The documented liver injury runs from transient enzyme elevation to prolonged cholestasis, and the published case series are the basis for watching ALT and bilirubin.
Confounders that make healthy people look ill
Three things distort results often enough to be worth naming before you panic at a number.
- Heavy training raises ALT and AST. Muscle damage leaks the same enzymes, so test at least 48 hours after a hard session, or your liver looks worse than it is.
- Creatine raises creatinine. That is a supplement artefact rather than a kidney problem, and eGFR formulas will misread it.
- Dehydration raises haematocrit. So does a hot day, and so does a long flight. A single high reading needs a repeat before it means anything.
Add one more: high-dose biotin, common in hair and nail supplements, interferes with several immunoassays. Stop it for 48 to 72 hours before testing, or the result may be quietly wrong.
How to read your own results
In peptide bloodwork, start with the reference range printed beside the number, then look at the direction of travel across your own results. A value inside range that has doubled since your baseline is more interesting than a value slightly outside range that has always sat there.
Then ask what else changed in the same window. Sleep, alcohol, a new supplement, a virus, three weeks of heavy training: all of those move markers. Because most people change several things at once, the honest reading is usually “something moved, and here are the candidates”.
Finally, take an abnormal result to a clinician rather than to a forum. That is not a disclaimer formality. A raised ALT or haematocrit has a differential diagnosis, and the person who can work through it has your history in front of them.
FAQ
What bloodwork should I get before starting peptides?
A full blood count, a lipid profile, liver enzymes, fasting glucose and HbA1c. Add testosterone, oestradiol and IGF-1 if you are looking at hormonal compounds. Take blood pressure on the same day, and keep the results.
How often should peptide bloodwork be repeated?
At week 4 to 6 for the fast movers, then at week 8 to 12 for the full panel, then 4 to 6 weeks and 3 months after you stop. That gives you four points rather than one snapshot.
Does peptide bloodwork prove a product is real?
No. Bloodwork shows your body’s response, not the contents of a vial. Only a batch-matched certificate of analysis speaks to what was in the product.
Which markers move most on growth hormone?
IGF-1 and fasting glucose. IGF-1 is the marker clinicians use to monitor growth hormone therapy, and glucose handling can worsen.
Do GLP-1 peptides affect kidney results?
They can, indirectly. The label advises checking renal function when vomiting or diarrhoea could cause dehydration, because that is what changes the numbers.
Why is my ALT high after training?
Because skeletal muscle contains the same enzymes. A hard session can raise ALT and AST for a few days, so test at least 48 hours after training.
Can I test while using creatine?
Yes, but read creatinine with care. Creatine supplementation raises creatinine without harming the kidney, and eGFR estimates will understate kidney function as a result.
What should I do with an abnormal result?
Repeat it first, under the same conditions, because single readings mislead. Then take both results to a clinician, with the dates and what changed in between.
The bottom line
Peptide bloodwork is ordinary bloodwork, used well. Get a baseline before anything changes, test the fast movers at week 4 to 6, and run the full panel again at week 8 to 12. Then repeat once you stop.
Read results as trends, respect the confounders, and remember the limit: no marker has been validated against most research peptides, because the human data does not exist. The panel tells you how your body is doing, and a clinician tells you what it means.
Last reviewed: November 2026 by Julian Hart.
This page is educational and is not medical advice. It does not tell you what to test for a medical reason, and it does not interpret your results. Blood tests, reference ranges and any decision about treatment belong with a qualified clinician. For related guides, see the peptide half-life chart and the other posts in the peptides section.
Sources
- MedlinePlus (NIH). IGF-1 (insulin-like growth factor 1) test: used to detect and monitor growth hormone disorders.
- Clemmons DR, et al. Interpreting growth hormone and IGF-I results. 2023.
- FDA. Ozempic (semaglutide) prescribing information: renal function monitoring, and the pancreatitis section.
- Cleveland Clinic Consult QD. GLP-1 agonists and pancreatitis: what the meta-analyses do and do not support.
- Meier C, et al. Serum estradiol after single dose hCG administration. 2005.
- NIH LiverTox. Androgenic steroids: the range of liver injury, from transient enzyme rises to prolonged cholestasis.
- Urhausen A, et al. Reversibility of the effects on blood cells, lipids, liver function and hormones in former anabolic-androgenic steroid abusers.
- MedlinePlus (NIH). Complete blood count and cholesterol levels, for what the standard panels measure.
